Sorrento Therapeutics Inc (SRNE)

[dia76ca]

I was pleased to see what the 10K said about COVISTIX.

"EUA submissions HAVE BEEN COMPLETED and are awaiting regulatory clearance from WHO, Canada(Health Canada), and the FDA."(p.7)

COVISTIX revenues will start to appear in the Q1 2022 report(about 2 months from now). I agree with those who predict the 2022 full year revenues should at least reach $750 million.

And I look for a lot of partnering in 2022. While Scilex will market non-opioid pain products in the US I look for a lot of marketing partnerships for ROW!

“With the exception of our subsidiary, Scilex Holding, we currently do not have any sales capabilities. We intend to license to, or enter into strategic alliances with, larger companies in the biopharmaceutical businesses or use the services of contract sales organizations (“CROs”), which are equipped to, market and/or sell our products, if any, through their well-developed marketing and sales teams and distribution networks. We intend to license some or all of our worldwide patent rights to more than one third party to achieve the fullest development, marketing and distribution of any products we develop.”

SEMDEXA revenues in the US could exceed a billion dollars in 2023 but with Fast Track and possibly Accelerated Approval could that revenue stream begin in late 2022? The sales team is already in the field in the US. And worldwide marketing partnerships should be expected in 2022 IMO! They could include upfront payments, milestone payments and licensing agreements.

COVISTIX, SEMDEXA, Scilex and a very exciting cancer portfolio will provide a lot of worldwide partnering opportunities! And we still have over 20.4 million CELU shares worth about $200 million(and rising) and an impressive portfolio which many Big Pharmas would love to have!
https://investors.sorrentotherapeutics.com/static-files/ded13448-aa64-4405-a2d9-de644cfe9dfc